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Abstract: In immuno-competent individuals, the natural course of chronic hepatitis C virus 
(HCV) infection is highly variable and 5%–30% of patients develop cirrhosis over 20 years. 
Co-infection with HCV and human immunodeﬁ  ciency virus (HIV) is an important prognos-
tic factor and associated with more frequent and accelerated progression to cirrhosis. Until 
recently HIV/AIDS-related complications were life limiting in patients co-infected with HCV; 
the introduction of highly active antiretroviral treatment (HAART) and the better prognosis 
of HIV infection has made HCV-related complications an emerging health problem in HCV/
HIV co-infected individuals. Treatment of chronic HCV infection has also evolved since 
the introduction of interferon-alpha. Recently, introduction of pegylated interferon-alpha 
(peginterferon-alpha) has resulted in an increase in sustained virus clearance rates of up to 
80% in selected genotypes and patient populations. The safety and efﬁ  cacy of modern anti 
HCV treatment regimens – based on peginterferon-alpha in combination with ribavirin – was 
evaluated in 4 controlled trials. Sustained clearance of hepatitis C virus can be achieved in up 
to 35% of patients with HIV/HCV co-infection, and novel HCV treatment regimens based on 
peginterferon-alpha have no negative effect on the control of HIV disease. In conclusion, if HIV 
infection is well controlled and CD4+ cell counts >100/mm3, treatment of chronic hepatitis C with 
peginterferon in combination with ribavirin is safe and should be given for 48 weeks regardless 
of the HCV genotype. Introduction of peginterferon-alpha has signiﬁ  cantly improved adherence 
to treatment and treatment efﬁ  cacy; in particular sustained virologic response in patients with 
HCV genotype 1 or 4 infection improved, but sustained viral clearance in only 7%–38% of 
patients infected with genotype 1 and 4 cannot be the ﬁ  nal step in development of effective 
treatments in patients with HCV/HIV co-infection.
Keywords: pegylated interferon-alpha, HIV, hepatitis C, ribavirin
Epidemiology
It is estimated that about 50 000 individuals in the United States are co-infected with 
human immunodeﬁ  ciency virus (HIV) and hepatitis C virus (HCV) (Sherman et al 
2002). The prevalence of HIV/AIDS in the US is about 800  000 (Sulkowski and 
Thomas 2003; Racial/ethnic disparities in diagnoses of HIV/AIDS 2006) compared 
with 4 million HCV infected people in the US (Alter 2006). The prevalence of 
chronic HCV infection among HIV-infected individuals varies between 15% and 90%, 
depending on the mode of viral transmission. HIV-infected individuals who received 
blood products or intravenous drug users who shared needles have a risk of HCV 
infection exceeding 90%. HCV/HIV co-infection rate among men having sex with 
men (MSM) is considerably lower (Terrault 2002), which is in accordance with data 
suggesting that the risk for sexual transmission of HCV is low (Neumayr et al 1999). 
The overall frequency of HCV infection in HIV-infected individuals was reported to 
be 16.4% in the Aids Clinical Trail Group (ACTG) paper (Sherman et al 2002), and 
about 30% in a European study (Rockstroh et al 2005).International Journal of Nanomedicine 2006:1(4) 400
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Pathophysiology
Spontaneous clearance of the virus occurs in only about 
15% of acute HCV infections, most of which are clinically 
asymptomatic (Lehmann et al 2004). If the virus cannot be 
cleared, progression of chronic hepatitis C to cirrhosis occurs 
in 5%– 30% of patients (Leone and Rizzetto 2005) over a 
period of 20 years (Seeff 2002). Risk factors associated with 
accelerated progression to ﬁ  brosis and cirrhosis include 
co-infection with HIV or hepatitis B virus (HBV), acquired 
infection after the age of 40, male sex, alcohol consumption 
of more than 50 g/day, hepatic steatosis, and immunosuppres-
sion (Chen and Morgan 2006). Interestingly, only 0%–2% 
of women show progression to cirrhosis 17–20 years after 
infection with anti-D-Rhesus immunoglobulin (Kenny-
Walsh 1999), which illustrates the difﬁ  culties in comparing 
the prognosis of different cohorts; mode of transmission, 
co-morbidities, and life-style factors may also inﬂ  uence 
disease progression.
With ∼30% of transplant recipients having chronic 
hepatitis C, until recently, HCV-cirrhosis was the most 
frequent indication for liver transplantation in the US and in 
Europe (Belle et al 1996). The incidence of end stage liver 
disease caused by hepatitis C is expected to further increase 
over the next 10 years as a result of the “silent epidemic” of 
HCV infection. The calculated annual risk for the develop-
ment of hepatocellular carcinoma in patients with chronic 
HCV infection is 1%–4%, attributable almost exclusively 
to patients in the cirrhotic stage of chronic HCV infection 
(Fattovich et al 1997). Besides hepatocellular carcinoma, 
decompensation of cirrhosis is another critical prognostic 
factor; 10-year survival after the ﬁ  rst decompensation is 
50%, compared with 80% in patients compensated cirrhosis 
(Fattovich et al 1997).
HCV has become a significant cause of morbidity 
and mortality in HCV/HIV co-infected individuals. Since 
the introduction of highly active antiretroviral therapy 
(HAART), prognosis of HIV infection has dramatically 
changed and chronic HCV infection with its associated 
complications is an emerging health problem (Lesens et al 
1999; Darby et al 1997; Bica et al 2001). As discussed 
above, in immuno-competent patients, hepatitis C usually 
has a relatively mild course, and liver-related deaths are 
only slightly more frequent in HCV infected individuals 
(Hoofnagle 2002). In contrast, hepatitis C may take a 
more severe course in HIV infected patients; accordingly, 
liver-related deaths are 16.7 times more frequent in HIV/
HCV co-infected people than in the general population 
and deaths due to liver cancer are 5.6 times more common 
(Darby et al 1997). Treatment of HCV infection is therefore 
of paramount importance in patients with HCV/HIV co-
infection.
Treatment
It is well established that interferon-alpha therapy has 
favorable effects on liver-related morbidity and mortality 
in chronic hepatitis C (Akuta et al 2005); improvement of 
hepatic histology, ie, ﬁ  brosis and inﬂ  ammation are used as 
surrogate markers for progression to cirrhosis in patients with 
chronic hepatitis C (Petrenkiene et al 2004). Favorable effects 
of interferon-alpha on disease progression were not limited 
to but most pronounced in patients with sustained virologic 
response (SVR), which is deﬁ  ned as serum HCV RNA con-
centration below the limit of detection (usually <50IU/mL) 
after 24 weeks after the end of treatment (Carlsson et al 2005; 
Ferenci et al 2005).
Decline in viral RNA during treatment with interferon-
alpha follows several phases: During the ﬁ  rst 2–3 days after 
initiation of treatment, hepatitis C virus RNA concentration 
in serum decreases rapidly (Jessner et al 2002, 2003). This 
early phase is followed by phases of less steep decline in 
viral load, which may reﬂ  ect 2 different mechanisms of 
action of interferon-alpha. Lack of early virologic response 
is the single most important negative predictor for sustained 
virologic response, where a ≥2log10 reduction in HCV RNA 
or an HCV RNA <50U/mL after 12 weeks of therapy is 
associated with a sustained virologic response in 0%–2% of 
patients (Dahari et al 2005).
Treatment options for hepatitis C have signiﬁ  cantly 
improved over recent years. Chronic infection with hepatitis 
C virus genotype 2 and 3 is now considered a curable disease 
in immuno-competent patients, and even patients with a more 
difﬁ  cult to treat genotype (1 and 4) can achieve sustained 
clearance rates of HCV RNA in about 40%. Three major 
steps led to this signiﬁ  cant improvement. First, the addition 
of ribavirin to interferon-alpha mono-therapy increased 
response rates from less than 20% to over 40%; second, the 
development of pegylated interferon-alpha (peginterferon-
alpha); and third, a better adherence to treatment (Abonyi 
and Lakatos 2005).
Pharmacology
After subcutaneous administration of unmodiﬁ  ed interferon-
alpha, which is rapidly absorbed, metabolized, and excreted 
by the kidney, maximum serum concentrations are observed 
after 8 hours (Chatelut et al 1999). Due to its short serum 
half-life, unmodiﬁ  ed interferon-alpha is recommended to be International Journal of Nanomedicine 2006:1(4) 401
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administered 3–7 times weekly (de Ledinghen et al 2002). 
Thus, modiﬁ  ed release of interferon-alpha was developed 
to meet patient expectations for less frequent parenteral 
drug administrations, and to increase sustained virologic 
response rates by improving patient adherence as well as 
more sustained drug concentrations with higher plasma 
concentrations.
Pegylation of proteins has become a widely used 
approach to optimize delivery and release of parenteral 
drugs. Pegylation is the covalent binding of a polyethyl-
ene glycol moiety to a protein. The size and structure of 
the polyethylene glycol (PEG) groups as well as the size 
and type of attachment determine the pharmacodynamic 
properties by interfering with receptor binding of interferon-
alpha, where in vitro binding decreases with increasing 
size of the PEG moiety. In contrast, absorption half-life 
increases, whereas volume of distribution and renal elimi-
nation decrease with an increasing size of the PEG moiety 
(Veronese and Pasut 2005). The size and structure of the 
PEG moiety can be tailored to change pharmacokinetic and 
pharmacodynamic properties of interferon-alpha (Pedder 
2003) (Figure 1).
Two different pegylated interferons have been approved 
for the treatment of chronic hepatitis C virus infection in 
HIV-infected individuals. They differ in size and type of PEG 
attachment, which translates into differences in pharmaco-
logical properties (Pedder 2003) (Table 1).
Peginterferon-alpha 2a (40 kD)
Peginterferon-alpha 2a is pegylated with a branched 40 kD 
PEG moiety and is a mixture of 4 main isomers, involving 
a PEG moiety covalently bound to the charged side group 
of lysines at position 31, 121, 131, or 134. Once-weekly 
administration of 180 μg of peginterferon-alpha 2a by 
subcutaneous injection in patients with chronic hepatitis 
C produces a mean maximum serum concentration (Cmax) 
of 25.6 μg/L, which is reached in a mean time of 45 hours 
after injection (Zeuzem et al 2003). The steady state is 
reached after about 5–8 weeks after initiation of therapy 
and the ratio of peak to through is about 1–0.75, indicating 
minor variations in drug concentrations at steady state. The 
volume of distribution is 8–12 L, in contrast to 31–73 L of 
unmodiﬁ  ed interferon-alpha 2a, suggesting a relatively high 
drug concentration in blood-rich organs such as in the liver 
(Harris et al 2001). Peginterferon-alpha 2a is excreted via 
the liver and kidney, where the renal clearance is 100-fold 
reduced compared with that of unmodiﬁ  ed interferon-alpha. 
The serum concentration proﬁ  le of peginterferon-alpha 2a 
is similar in patients with impaired renal function when 
compared with patients with normal renal function. In 
patients with end stage renal disease and chronic hemo-
dialysis, dose reduction is recommended, because with 
75% of the peginterferon-alpha 2a dose (135 μg once 
weekly) similar serum concentration proﬁ  les have been 
found when compared with individuals with unimpaired 
kidney function. Terminal half-life of peginterferon-alpha 
2a is similar in cirrhotic patients and healthy volunteers 
(Zeuzem et al 2003).
Table 1 Pharmacokinetic parameters of interferons
  Peginterferon-alpha 2a Peginterferon-alpha 2b Interferon-alpha 2a Interferon-alpha 2b
Asorption half-life 50 h 4.6 h 2.3 h 2.3 h
Volume of distribution 8–12 l 0.99 L/kg 31–73 L 1.4 L/kg
Clearance 60–100 mL/h 22 mL h–1 kg–1 6600–29 200 mL/h 231.2 mL h–1 kg–1
Elimination half-life 65 h 40 h 3–8 h 4 h
Adapted from Zeuzem S, Welsch C, Herrmann E. 2003. Pharmacokinetics of peginterferons. Semin Liver Dis, 23(Suppl 1):23-8. By permission.
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Peginterferon-alpha 2b (12 kD)
Peginterferon-alpha 2b is a heterogeneous mixture of 
derivatized protein isoforms, where a linear PEG moiety 
is covalently attached to lysines, serines, threonines, 
histidines, or the C-terminal cysteine. The single most 
abundant positional isoform is an interferon-alpha 
poly-peptide, where the PEG molecule is bound to a histi-
dine at position 34. This isoform has a high in vitro antiviral 
activity, but is also the isoform that is most susceptible 
to hydrolysis, because of the urethane bond which is the 
covalent bond conjugating the PEG to the polypeptide chain 
(Glue et al 2000). The relatively lower molecular weight 
and the more ready hydrolysis are the molecular basis for 
the shorter elimination half-life (∼40 h for peginterferon-
alpha 2b versus >65 h for peginterferon-alpha 2a). The 
volume of distribution of unmodiﬁ  ed interferon-alpha 
2b is 1.4-fold that of peginterferon-alpha 2b; but the dis-
tribution volume of peginterferon-alpha 2b is generally 
higher than that of peginterferon-alpha 2a, which neces-
sitates dosing adjusted to body weight (Glue et al 2000). 
Elimination routes are renal (30%) and hepatic, as well as 
intracellular degradation upon binding to the interferon-
alpha receptor (Gupta et al 2002). Peginterferon-alpha 2b 
dose adjustment is recommended in patients with impaired 
renal function (creatinine clearance <50mL/min) (Patel and 
McHutchison 2001).
In summary, PEG modiﬁ  es the pharmacokinetic and 
pharmacodynamic properties of the protein. The molecular 
weight of the PEG moiety is directly proportional to the 
serum half-life of the protein, and indirectly proportional to 
its half-life in the serum. The pharmacokinetics are further 
determined by the type and stability of PEG attachment to 
the protein.
Pharmacodynamics
PEG has unfavorable effects on the binding of interferon-
alpha to its target molecules (Grace et al 2005). However, 
pegylated interferons still have improved pharmacodynamic 
properties and the sustained virologic response rates are 
higher with pegylated than with unmodiﬁ  ed interferon-alpha 
(Heathcote and Main 2005), which could be attributed to the 
altered pharmacokinetics. Interferon-alpha has two major 
routes of action: the direct antiviral effect of interferon-alpha 
is partly exerted by activation of double-stranded RNA-
activated protein kinase (PKR) and with induction of the 
antiviral 2'5'-oligoadenlyate synthase (2'5' OAS) pathway, 
which is used as a surrogate marker for interferon-alpha 
activity in vivo (Murashima et al 2000). The OAS pathway 
is induced by double stranded RNA; and represents an 
endogenous antiviral defense mechanism, which blocks 
viral replication by expression of an mRNA endonuclease. 
Additionally, viral life-cycle is inhibited directly (Chung 
et al 2001) by host immune modulation (Thomas et al 
1999). Interferon-alpha induces activation of macrophages 
natural killer cells as well as cytotoxic T-cells (Dianzani 
1993). In chronic hepatitis C, interferon-alpha produces a 
Th1-type immune response with induction and maintenance 
of an HCV-speciﬁ  c CD4+ T-helper cell response (Kamal 
et al 2002).
Riabvirin
Ribavirin (1-ß-D-ribofuranosyl-1,2,4-triazole) is a broad 
spectrum antiviral nucleoside analog, which is phosphory-
lated intracellularily to ribarivin monophosphate, ribavirin 
diphosphate and ribavirin triphosphate (Morse et al 1993). 
Although its precise mode of action in vivo is still unknown, 
in vitro evidence suggests that ribavirin monophosphate 
inhibits inosine monophosphate dehydrogenase which 
results in decreased synthesis of guanosine triphosphate 
(GTP), thereby blocking virus replication, because GTP 
is required for translation, virus transcription, and RNA 
synthesis. Alternatively, it has been suggested that ribavirin 
triphosphate is utilized by viral RNA-dependent RNA poly-
merase and causes lethal mutagenesis of the viral genome 
(Graci and Cameron 2006). The antiviral effect of ribavirin 
has further been ascribed to direct inhibition of viral RNA 
polymerase by ribavirin triphosphate. It is unlikely that the 
proposed inhibition of viral transcript capping by ribavirin 
is of great relevance in vivo because translation of HCV 
genotype 1b mRNA is CAP independent and mediated 
via an internal ribosomal entry site (IRES) (Hellen and 
Pestova 1999).
Another mode of action is that ribavirin modulates the 
immune response which results in a reduction of immune-
mediated tissue damage via reduced interferon-gamma 
expression (Bergamini et al 2001) or reduction of IL-10 
expression (Tam et al 1999) and thereby altering Th1/Th2 
subset balance.
Despite the uncertainties about its exact mode of action, 
ribavirin signiﬁ  cantly improves the efﬁ  cacy of antiviral 
treatment as compared with interferon-alpha alone and has 
therefore evolved to be a cornerstone of antiviral treatment 
in chronic hepatitis C (Idea and Bellobuono 2002). In con-
trast, its widespread pharmacological effects have delayed 
the advance of ribavirin for hepatitis C in patients receiving 
antiretroviral treatment to control HIV infection.International Journal of Nanomedicine 2006:1(4) 403
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Ribavirin/anti HIV drug interactions
In vitro, ribavirin inhibits intracellular phopsphorylation 
of nucleoside reverse transcriptase inhibitors (NTRIs) 
lamivudine (3TC), stavudine (d4T), and zidovudine (ZDV) 
used for treatment of HIV infection, thus potentially reducing 
their antiretroviral activity (De Clerq 2004). However, inde-
pendent studies have conﬁ  rmed that the pharmacokinetic 
parameters of NTRIs are not significantly different in 
patients receiving PEG-interferon-alpha monotherapy or 
a combination therapy with ribavirin (Margot and Miller 
2005; Rodriguez-Torres et al 2005). The in vitro antagonism 
of ribavirin and NTRIs has delayed the use of ribavirin in 
HCV/HIV co-infected patients, but no negative impact of 
stavudine-ribavirin combination on anti-retoviral efﬁ  cacy 
could be found in a recent randomized controlled trail 
(Salmon-Ceron et al 2003).
Pharmacokinetics of ribavirin
A recent study of mean steady state pharmacokinetic 
parameters of ribavirin in HCV/HIV /infected patients 
showed that potential drug interactions are of particular 
importance in the treatment of HIV infection (Rodriguez-
Torres et al 2005). After oral administration, ribavirin is 
extensively and rapidly absorbed and transported actively 
by gastrointestinal N1 sodium-dependent nucleoside 
transporters in the duodenum and proximal jejunum 
(Glue 1999). Ribavirin is typically administered orally 
in doses of 800–1200 mg/day divided in 2–3 doses. 
A linear relationship between dose and AUC can be 
observed, but the bioavailability of ribavirin increases 
with high fat intake. The antiviral effect of ribavirin has 
been observed to depend signiﬁ  cantly on plasma concen-
tration and dosage (Kato et al 2005). Following a 600-mg 
dose, the mean maximum concentration in plasma, Cmax, 
was observed to be 782 ng/mL. The mean time to the 
maximum concentration, tmax was ∼1.5 h. The half-life of 
the distribution phase was ∼3.7 h. The terminal elimina-
tion phase was long with a mean ﬁ  nal concentration time 
point following single dosing at ∼100 h. The elimination 
half-life was 79 h. The mean area under the curve, AUC, 
was 13394 ng mL–1 h–1 (Liu et al 1996).
Viral kinetics
The study of viral kinetics can give insight into the 
pathogenesis of viral disease and may allow prediction of 
treatment response early during treatment (Lee et al 1998; 
Tsubota et al 2005). Mathematical models of viral kinetics in 
patients with HIV infection have predicted that infected cells 
have an average life span of 2.2 days and plasma virions were 
estimated to have a mean life span of 0.3 days (Perelson et al 
1996). In chronic HCV infection, the viral mRNA is relatively 
stable, where the rate of viral release from hepatocytes equals 
the infection rate of new hepatocytes. Although, without 
intervention, the mean serum concentration remains fairly 
constant, chronic hepatitis C is a highly dynamic process, 
where the half-life of virions has been estimated to be 3 h 
(Herrmann and Zeuzem 2006).
Hepatitis C viral dynamics change rapidly after 
administration of interferon-alpha. The study of viral kinetics 
in patients with chronic hepatitis C who show sustained 
virologic response to interferon-alpha treatment has shown 
that the decline in viral RNA follows at least two phases, 
where an initial steep decline in HCV RNA during the 
ﬁ  rst weeks of treatment (immediate virologic response), is 
followed by a phase of less steep decline. According to one 
theory, is has been suggested that antiviral cytokines released 
from T cells can clear the cells of virus in a non cytopathic 
manner. This virus-clearing mechanism would have the 
advantage to the host that liver cells are lost at a slower rate. 
Regardless of the exact mode of action, the immediate effects 
of interferon-alpha are of prognostic value for the prediction 
of sustained virologic response (Pawlotksy 2006).
A poor interferon-alpha effect (<90% effectiveness; 
<1 log drop in virus RNA serum concentrations) after the ﬁ  rst 
drug dose is predictive for non-SVR after interferon-alpha 
therapy for 48 weeks. This observation was made in patients 
treated with interferon-alpha monotherapy, combination therapy, 
and peginterferon-alpha therapy. In several studies, lack of 
a ≥1 log10 decline within 24 h or a less than 30% decrease in 
viral load was associated with failure to clear virus early in 
therapy as well as non-SVR (Ferenci et al 2005).
Although the immediate effect of interferon-alpha is of 
some predictive value, it is standard practice to assess early 
virologic response after 4 weeks of treatment for the predic-
tion of sustained virologic response (Tsubota et al 2005). 
Accordingly, the pharmacokinetics of peginterferon-alpha 
are such that interferon-alpha serum concentrations are 
maintained after 4 weeks (Caliceti 2004). The predictive 
value of early virologic response after 4 weeks of treatment 
has now been demonstrated in several studies – also in the 
setting of HIV/HCV co-infection (Carrat et al 2004; Chung 
et al 2004; Torriani et al 2004).
According to changes in serum HCV RNA concentrations, 
within the ﬁ  rst 4 weeks of treatment, patients have been 
grouped into ﬂ  at partial responders, slow partial responders International Journal of Nanomedicine 2006:1(4) 404
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and rapid early responders (RER). In the latter group tests 
for HCV viral RNA in serum become negative after 4 weeks 
of treatment, whereas in slow partial responders a gradual 
second phase decline of virus mRNA follows an initial rapid 
1–2 log drop in serum HCV mRNA concentrations. In ﬂ  at 
partial responders, no further decline in HCV mRNA serum 
concentrations can be found after an initial rapid 1–2 log10 
decline in serum HCV mRNA after 4 weeks of treatment. 
This response patterns are in contrast to the response 
observed in without a signiﬁ  cant drop in viral load a relapse 
is observed under treatment and referred to as non-response 
(Ferenci 2003, 2004; Ferenci et al 2005).
In contemporary management of chronic hepatitis C 
monoinfection, prediction of treatment response is based on 
the HCV genotype, the initial serum virus RNA concentration 
and on the viral kinetics under treatment with peginterferon-
alpha as measured at the start of treatment, after 4 weeks 
12 weeks, and 24 weeks of treatment (Pawlotsky 2006). 
For HCV/HIV co-infected patients the predictive value of 
rapid early virologic response (4 weeks) and early virologic 
response (12 weeks) was assessed in a recent clinical trial 
(PRESCO trial) (Nunez et al 2005). The results of this trial 
demonstrate that lack of early virologic response (<1 log10 
decline in serum HCV RNA concentrations) had a negative 
predictive value 63% for genotype 1 and 2 and 100% for 
genotype 2/3 that the patient would have no early virologic 
response after 12 weeks. Besides, HCV genotype ribavirin 
dose was the only factor independently associated with 
early virologic response (Nunez et al 2005). In larger trials, 
0%–0.2% of HCV/HIV co-infected patients without early 
virologic response 12 weeks after the start of treatment 
achieved a sustained viral clearance (Chung et al 2004; 
Torriani et al 2004).
In summary, quantiﬁ  cation of serum HCV mRNA before 
and during interferon-alpha treatment allows tailoring of 
treatment and prediction of treatment response and has 
therefore advanced to an important tool in contemporary 
patient management.
Effect of peginterferon-alpha 
on HIV disease
The safety and efﬁ  cacy of peginterferon-alpha in HCV/
HIV co-infected patients was the subject of 4 randomized 
controlled trials. In the ACTG trial (Chung et al 2004), where 
HIV mRNA levels at baseline and at 24 weeks were only avail-
able from only a subgroup of patients, 11% of patients treated 
with interferon-alpha and ribavirin became HIV RNA negative 
during treatment. In patients treated with peginterferon-alpha 
2a and ribavirin 14% who had tested initially positive for 
HIV RNA became negative during the treatment period. 
In contrast 6% and 5% of patients initially tested negative 
for HIV RNA, but became positive during treatment with a 
combination of ribavirin and standard interferon-alpha or 
peginterferon-alpha respectively.
For the management of HIV infection CD4+ T cell counts 
are of greater prognostic value than HIV RNA levels, and 
patients enrolled in the ACTG trial on average showed a 
decrease in CD4+ cells by >100 cells/mm3 during the ﬁ  rst 
24 weeks of treatment with peginterferon-alpha 2a and 
ribavirin. No further decrease in CD4+ cells was observed 
after 24 weeks and after completion of treatment a return 
to baseline was observed. Since the risk of opportunistic 
infections and AIDS deﬁ  ning events occur more frequently 
when CD4+ cell counts fall, the question if peginterferon-
alpha 2a treatment should be withheld from patients with a 
low CD4+ T cell count has been raised. Subgroup analysis 
of those patients enrolled in ACTG who had CD4+ T cell 
counts below 200/μm³ showed that baseline CD4+ cell count 
was not predictive of SVR – and SVR was in fact higher in 
those patients who had a CD4+ cell count of <200 cells/mm3. 
Further the overall incidence of AIDS deﬁ  ning events was 
1% in the ACTG trial and not increased in those patients 
who had cell counts of <200 cells/mm3. Based on these data, 
the authors conclude that treatment of chronic HCV infec-
tion with peginterferon-alpha 2a and ribavirin should not be 
withheld from patients with low CD4+ cell counts; however, 
patients with CD4+ cell counts of less than 100 cells/mm3 
were excluded from this and other studies.
The ﬁ  ndings by Torriani et al (2004) regarding CD4+ cell 
counts were similar to the ﬁ  ndings in the ACTG trial and a 
uniform decrease was observed in all three treatment groups 
during treatment, whereas the relative proportion of CD4+ 
cells increased. In a total of 10 patients AIDS-deﬁ  ning events 
occurred during the study, a calculated frequency of 1.2%, 
which is not signiﬁ  cantly higher than expected and the rela-
tive frequency, which was equal in all three treatment arms. 
From study entry to week 24, the median CD4+ cell count 
decreased by 130 cells/mm3. However, the percentage of 
CD4+ cells increased in both groups and the absolute CD4+ 
cell count did not decrease further after week 24.
The effect of peginterferon-alpha 2b on HIV RNA was 
comparable with that of peginterferon-alpha 2a; however, 
the higher efﬁ  cacy of peginterferon-alpha as compared with 
standard interferons also caused a more pronounced increase 
in HIV RNA, although the differences did not reach statistical 
signiﬁ  cance (Carrat et al 2004).International Journal of Nanomedicine 2006:1(4) 405
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In the study by Laguno et al (2004) CD4+ cell counts fell 
on average from 560 cells/mm3 to 331 cells/mm3 upon treat-
ment with interferon-alpha, and no statistically signiﬁ  cant 
differences between interferon-alpha 2b or peginterferon-
alpha 2b could be identiﬁ  ed. Regarding HIV viral load, “no 
meaningful” changes were found.
Based on these data, it is generally assumed that 
combination therapy with peginterferon-alpha in patients 
with controlled HIV disease and CD4+ cell counts of 
>100/mm3 is safe and not associated with loss of HIV 
disease control.
Results of clinical trials
The safety and efﬁ  cacy of peginterferon-alpha in HIV/HCV 
co-infected individuals was tested in 4 randomized controlled 
trials (Charrat et al 2004; Chung et al 2004; Torriani et al 
2004). The key characteristics of these trials are summarized 
in Table 2. The rate of sustained virologic response after 
treatment with either peginterferon-alpha 2a or peginterferon-
alpha 2b in combination with ribavirin was signiﬁ  cantly 
lower in HCV/HIV co-infected as compared with HCV 
monoinfected patients in all trials. This is of particular inter-
est in the light of the well compensated HIV infection in all 
patients included in the studies, in whom CD4+ cell counts 
were relatively high (>100 cells/μL).
Efﬁ  cacy
In the European multicenter study, 416 patients with HIV/
HCV co-infection (39% of patients had cirrhosis or bridging 
ﬁ  brosis) were randomized to receive either interferon-alpha-
2b (3 million units 3 times a week) or peginterferon-alpha 
2b (1.5 μg/kg once weekly) plus 800 mg/day ribavirin. SVR 
Table 2 Key characteristics of clinical trials on safety and efﬁ  cacy of peginterferon-alpha in HIV/HCV co-infected individuals
Study Chung et al 2004
(ACTG 5071)
Torriani et al 2004
(APRICOT)
Carrat et al 2004
(RIBAVIC)
Laguno et al 2004
(Barcelona)
N 66 868 412 95
Design (weekly interferon-alpha 
dose)
peginterferon-alpha 2a
vs
interferon-alpha 2a
peginterferon-alpha 2
vs
interferon-alpha 2aa
peginterferon-alpha 2b
vs
standard interferon-alpha 2b
peginterferon-alpha 2b
vs
standard interferon-alpha 2b
Duration 48 weeks 48 weeks 48 weeks 48 weeks
(genotype 2/3 24 weeks)
Ribavirin dose ≤1000 mg (escalating) 800 mg 800 mg 1200 mg
(adjusted to body weight)
Peginterferon-alpha
dose per week
180 μg
peginterferon-alpha 2a
180 μg
peginterferon-alpha 2a
1.5 μg/kg
peginterferon-alpha 2b
100–150 μg
peginterferon-alpha 2b
Standard interferon-
alpha dose per week
3 × 6 million units 3 × 3 million units 3 × 3 million units 3 × 3 million units
Therapy completed 88% 61% 57% 81%
Treatment discontinued
due to side-effects
11% 13% 17% 16%
Dose reduction in
peginterferon-alpha group
6% 13%b 16% 25%
SVR (week 72) genotype 1 (or 4)
in peginterferon-alpha group
14% 29% 17% 38%
SVR (week 72) genotype 1 (or 4)
in standard interferon-alpha group
6% 7% 6% 7%
SVR (week 72) genotype 2 or 3
in peginterferon-alpha group
11% 62% 44% 53%
SVR (week 72) genotype 2 or 3
in standard interferon-alpha group
5% 17% 43% 47%
Antiretroviral therapy 86% 84% 83% 88%
Cirrhosis or advanced ﬁ  brosis 10% 14% 39% 30%
a3rd treatment arm peginterferon-alpha 2b w/o ribavirin.
btreatment with granulocyte colony stimulating factor and erythropoietin was permitted if leucopenia and anemia occurred during treatment.
Abbreviation: SVR, sustained virologic response.International Journal of Nanomedicine 2006:1(4) 406
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rates in the group who had received Peginterferon-alpha 
were 27% compared with 20% of patients receiving standard 
interferon-alpha (Carrat et al 2004).
In the Adult AIDS Clinical Trials Group trial 5071, 
133 patients were randomized to receive 48 weeks of combi-
nation therapy with either interferon-alpha 2a 3 million units 
3 times a week or peginterferon-alpha 2a 180 μg once a week 
plus ribavirin 600 mg/day initially, which was increased if 
tolerated. Peginterferon-alpha 2a was superior to standard 
interferon-alpha, and the frequency of SVR in the peginter-
feron-alpha ribavirin group was 14% for genotype 1 infected 
patients. In contrast, for genotype 2 and 3 the frequency of 
SVR was 73%, in patients receiving a 48-week treatment 
course. In the PEG-interferon-alpha group, 27% achieved 
SVR compared with only 12% in the standard interferon-
alpha group (Chung et al 2004).
In the international AIDS Pegasys Ribavirin Interna-
tional Co-infection Trial, 868 HCV/HIV co-infected patients 
were randomized in 3 groups to receive 48 weeks of treat-
ment with either standard interferon-alpha 2a (3 million 
units 3 times a week) plus ribavirin, Peginterferon-alpha 
2a (180 μg/week) plus placebo or plus ribavirin, respec-
tively. Peginterferon-alpha 2a in combination with ribavirin 
proved superior (SVR 40% for all genotypes) to peginter-
feron-alpha 2a without ribavirin (SVR 12% for all geno-
types). In patients with genotype 1 infection treated with 
peginterferon-alpha 2a 29% achieved SVR, whereas 62% in 
patients with genotypes 2 or 3 had a sustained virus clear-
ance after treatment with Peginterferon 2a plus rivabirin 
(Torriani et al 2004).
Finally, the Barcelona single center randomized controlled 
trial included 95 patients; 30% of whom had bridging ﬁ  brosis 
or cirrhosis upon liver biopsy before treatment. Patients 
were randomized to receive either peginterferon-alpha 2b or 
interferon-alpha 2b, both with ribavirin. Peginterferon-alpha 
doses were adjusted to body weight with 100 μg/week for 
patients <75 kg or 150 μg/week for patients ≥75 kg; ribavirin 
doses were 800 mg, 1000 mg, or 1200 mg for body weights 
<60 kg, 60–75 kg, and >75 kg, respectively. In accordance 
with treatment protocols for HCV mono-infected patients, 
genotype 1 infections were treated for 48 weeks, while 
patients with genotypes 2 or 3 were treated for 24 weeks. In 
patients with genotypes 1 and 4, SVR was achieved in 38% 
of peginterferon-alpha group versus 7% in the conventional 
interferon-alpha group. In patients with genotype 2 and 
3 infection SVR was achieved in 53% for the peginterferon-
alpha group versus 47% for the standard interferon-alpha 
group (Laguno et al 2004).
In summary, all 4 trials support a recommendation of 
PEG-interferon-alpha/ribavirin combination therapy for 
patients with HCV/HIV co-infection. Detailed analysis of 
the studies suggests that the dose of ribavirin should be 
adjusted to body weight and a correlation between ribavirin 
dose and sustained virologic response rate can be observed; 
however this has yet to be formally tested in patients with 
HIV/HCV co-infection. The results of one trial suggests that 
a 24-week treatment regimen for genotypes 2 and 3 may 
be sufﬁ  cient for patients with genotypes 2 and 3, but this 
has not yet entered the canon of medicine and international 
expert panels still suggest a full 48-week treatment regimen 
for should be given in patients with HCV/HIV co-infection 
regardless of the genotype. The majority of patients do not 
respond to therapy, but the high mortality from liver diseases 
in HIV-infected patients supports the urgent introduction of 
HCV treatment. Antiviral treatment for hepatitis C in HIV 
co-infected patients should be introduced only after stabili-
zation of HIV by antiviral treatment for HIV. In patients in 
whom no anti-viral treatment for HIV is required, treatment 
for HCV should be introduced immediately.
Predictors of response
As discussed above, HCV genotype is an important prog-
nostic factor in HCV mono-infected individuals, and the dis-
parity in response rates between different genotypes is even 
more pronounced in patients with HIV/HCV co-infection, 
where highest relapse rates in genotype 1 infected patients 
account for this difference. For genotypes 2 and 3 a 24-week 
combination therapy was sufﬁ  cient to achieve sustained 
virologic response in 35% of patients with genotype 3; SVR 
was higher (52%) in patients treated for 48 weeks. Based 
on these data a 48-week treatment regimen was suggested 
also for patients with genotype 2 or genotype 3 infection 
(Laguno et al 2004).
Remarkably, neither African race nor high body mass 
index, which are well established negative predictors of 
SVR in patients with chronic hepatitis C alone, have been 
associated with decreased SVR in APRICOT.
In HCV mono-infected patients and HCV/HIV co-
infection, prediction of sustained virologic response is fur-
ther made on the basis of viral load; the prognosis to clear 
the infection is worst in genotype 1 infected individuals 
with high viral load (>800  000 IU/mL), where sustained 
virologic response rates of only 18% were achieved. 
Interestingly the HIV factors, such as CD4+ cell count at 
baseline and the non-use of antiretroviral therapy, did not 
affect SVR rates. In non-responders it has been suggested International Journal of Nanomedicine 2006:1(4) 407
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that peginterferon-alpha/ribavirin combination treatment 
may still have favorable effects on disease progression, as 
suggested by the observed improvement of ﬁ  brosis scores 
which were found in a subgroup of patients who were 
biopsied before and after treatment (Torriani et al 2004). 
However, if this histological improvement translates to an 
improved clinical outcome is still unclear.
A careful risk to benefit analysis in HCV/HIV co-
infected patients requires prediction of treatment response by 
evaluating early virologic response by at week 12. It has been 
shown that early virologic response assessed after 12 weeks 
of treatment is the strongest predictive factor. Patients who do 
not show a 2 log10 decline or undetectable serum HCV RNA at 
week 12 when compared with baseline viral load, are highly 
unlikely to achieve sustained virologic response (Chung et al 
2004). In such patients discontinuation of treatment may be 
considered if the tolerability of treatment is poor.
It should be noted that adherence to treatment is a major 
factor determining treatment response. Psychiatric adverse 
events including depression are well known side-effects of 
interferon-alpha; patients should therefore be managed in an 
optimal setting of experts in different ﬁ  elds to improve adher-
ence to treatment. Consultation of a psychiatrist before and 
during treatment as well as antidepressants have been shown 
to ameliorate side-effects and improve treatment adherence 
(Musselman et al 2001; Schaefer et al 2003).
Safety and tolerability
Ribavirin causes dose dependent hemolysis, which is often 
dose limiting in HCV mono-infection. Studies have shown 
that a sufficient ribavirin dose is crucial for achieving 
optimal SVR (Manns et al 2001; Hadziyannis et al 2004). 
Since hemolysis is a signiﬁ  cant problem for HIV-infected 
patients receiving HAART, the ribavirin doses were rela-
tively low in all 4 randomized trials, and in the trial published 
by Chung et al (2004) dose reduction was allowed of ribavirin 
if hematological side-effects occurred. This partly explains 
the relatively low rate of SVR in HCV/HIV co-infected 
patients and future studies will show is new drugs such as 
viramidine whose potency to induce hemolysis is lower, 
will result in an improvement of SVR rates in this difﬁ  cult 
to treat patient population (Gish 2006). Further the use of 
erythropoietin may be an alternative to maintain ribavirin in 
some pateints (Lebray et al 2005).
Tolerability data for peginterferons are also available 
from these trials and treatment interruption due to side-
effects or abnormal laboratory ﬁ  ndings was reported in 
11%–17% (Table 2);  a statistically signiﬁ  cant difference 
in side-effects between peginterferon-alpha and standard 
interferon-alpha could not be found in any of the trials. 
The most common side-effects apart from anemia included 
neutropenia, thrombocytopenia, influenza like symp-
toms, asthenia, anorexia, headache, myalgia, depression, 
insomnia, alopecia, and injection site reactions, as well 
as altered thyroid function. Since some of the side-effects 
are dose dependent, doses of peginterferon-alpha and/or 
ribavirin were reduced if necessary. The frequencies of 
dose reduction were higher in patients receiving pegin-
terferon-alpha preparations and are shown in Table 2. 
Although tolerability of peginterferon-alpha 2a appears 
slightly superior, treatment was discontinued in 29% in 
one trial, despite the use of hematopoietic growth factors 
(granulocyte colony stimulating factor and erythropoietin) 
being allowed in this trial (Chung et al 2004).
Pancreatitis was another complication observed during 
peginterferon-alpha/ribavirin treatment in HIV patients 
receiving HAART. Inhibition of inosine-5'-monophosphate 
dehydrogenase by ribavirin facilitates conversion of didano-
sine to its active metabolite and thus causes potential mito-
chondrial toxicity, for which hyperlactatemia is a surrogate 
marker. The occurrence of pancreatitis in a total of 24 patients 
in all multicenter trials together (Charrat et al 2004; Chung 
et al 2004; Torriani et al 2004) in patients receiving peginter-
feron-alpha/ribavirin and a didanosine based HART regimen 
led to the recommendation to change the HAART regimen 
if didanosine is used, before peginterferon-alpha/ribavirin 
treatment is started in HCV/HIV co-infected patiens (Manns 
and Wedermeyer 2004).
Recommendations
Based on the existing body of evidence and in accordance 
with published management guidelines, individuals co-
infected with HCV and HIV should be evaluated for the 
need for treatment of HIV ﬁ  rst and, if anti-retroviral therapy 
is not required, treatment for HCV should be introduced. If 
anti-retroviral treatment is required, this should be started 
before any anti-viral therapy for hepatitis C is given and the 
HIV disease should be stabilized before introducing treatment 
with peginterferon-alpha and ribavirin (Heathcote and Main 
2005) for 48 weeks. The results from clinical trials show 
that response rates increase with increasing ribavirin doses; 
ribavirin doses should therefore be adjusted to body weight 
and severity of side-effects (anemia and leucopenia). The 
use of hematopoietic growth factors may help to maintain 
patients on sufﬁ  ciently high ribavirin doses when anemia of 
leucopenia develops. Other side-effects such as depression, International Journal of Nanomedicine 2006:1(4) 408
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ﬂ  u-like symptoms, and thyroid dysfunction must be moni-
tored carefully and treated symptomatically or treatment 
stopped if required. When HIV treatment is started the use 
of didanosine should be avoided because of an increased 
risk of pancreatitis.
Although introduction of peginterferon-alpha and 
ribavirin have both signiﬁ  cantly advanced the treatment of 
hepatitis C in HIV-infected patients, it will be essential to 
view peginterferon-alpha as “a signiﬁ  cant progress but not 
the ﬁ  nal step” (Manns and Wedemeyer (2004).
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